关注
Shuai Li
Shuai Li
NYU Langone Medical Center
在 nyumc.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation
J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ...
Cancer discovery 8 (2), 216-233, 2018
5972018
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ...
Nature medicine, 1, 2018
4522018
Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids
RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ...
Cancer discovery 8 (2), 196-215, 2018
4522018
Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway
KJ Kurppa, Y Liu, C To, T Zhang, M Fan, A Vajdi, EH Knelson, Y Xie, ...
Cancer Cell 37 (1), 104-122. e12, 2020
3342020
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
C Ambrogio, J Köhler, ZW Zhou, H Wang, R Paranal, J Li, M Capelletti, ...
Cell, 2018
2652018
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
C Fedele, S Li, KW Teng, CJR Foster, D Peng, H Ran, P Mita, MJ Geer, ...
Journal of Experimental Medicine 218 (1), 2020
1732020
CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer
H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ...
Cancer Cell 37 (1), 37-54. e9, 2020
1732020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ...
Cancer Cell, 2019
1642019
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao, Y Zhang, H Ji, ...
Clinical Cancer Research, clincanres. 1875.2017, 2018
1332018
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li, SD Wardwell, ...
Cancer Discovery, 2021
1302021
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
H Zhang, CF Brainson, S Koyama, AJ Redig, T Chen, S Li, M Gupta, ...
Nature communications 8, 14922, 2017
1112017
Suppression of adaptive responses to targeted cancer therapy by transcriptional repression
M Rusan, K Li, Y Li, CL Christensen, BJ Abraham, N Kwiatkowski, ...
Cancer discovery 8 (1), 59-73, 2018
1052018
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
W Li, S Ren, J Li, A Li, L Fan, X Li, C Zhao, Y He, G Gao, X Chen, S Li, ...
Lung Cancer 84 (3), 295-300, 2014
1032014
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
DM Briere, S Li, A Calinisan, N Sudhakar, R Aranda, L Hargis, DH Peng, ...
Molecular Cancer Therapeutics, 2021
1012021
BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer
DO Adeegbe, S Liu, M Hattersley, M Bowden, CW Zhou, S Li, R Vlahos, ...
Cancer immunology research, canimm. 0077.2018, 2018
952018
In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis
Q Wu, Y Tian, J Zhang, X Tong, H Huang, S Li, H Zhao, Y Tang, C Yuan, ...
Proceedings of the National Academy of Sciences 115 (17), E3978-E3986, 2018
902018
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
J Deng, A Thennavan, I Dolgalev, T Chen, J Li, A Marzio, JT Poirier, ...
Nature Cancer, 1-12, 2021
812021
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
KH Tang, S Li, A Khodadadi-Jamayran, J Jen, H Han, K Guidry, T Chen, ...
Cancer discovery 12 (1), 47-61, 2022
662022
Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
S Li, S Liu, J Deng, EA Akbay, J Hai, C Ambrogio, L Zhang, F Zhou, ...
Clinical Cancer Research, clincanres. 3438.2017, 2018
632018
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
H Choi, J Deng, S Li, T Silk, L Dong, EJ Brea, S Houghton, D Redmond, ...
Cell reports 27 (3), 806-819. e5, 2019
602019
系统目前无法执行此操作,请稍后再试。
文章 1–20